文献速递膀胱癌与上尿路尿路上皮癌

新辅助化疗联合经尿道电切保留膀胱:15年随访结果

Neoadjuvant Chemotherapy With Transurethral Resection for Bladder Preservation: 15-Year Follow-Up of the Retained Bladder.
PubMed 文献 · J Urol · 2025-08-06

该研究回顾性分析了101例符合保留膀胱理想标准并达到临床完全缓解的肌层浸润性膀胱癌患者,接受顺铂为基础化疗和经尿道电切,随访超过10年。15年膀胱癌死亡风险为11%,膀胱切除风险为11%,其他原因死亡风险为44%。保留膀胱结局近似40:40:10:10分布,局部复发可晚于10年,需终身监测。

要点

  • 15年膀胱癌死亡风险11%,膀胱切除风险11%。
  • 其他原因死亡竞争风险达44%,决策需权衡。
  • 局部复发可晚于10年,需终身 surveillance。

核心结论

  • 对于符合既定理想标准的肌层浸润性膀胱癌患者,新辅助化疗联合经尿道电切保留膀胱是可行选择。

研究设计与样本

  • 机构回顾性研究,纳入101例前瞻性监测的患者,1994-2015年接受顺铂为基础化疗和经尿道电切,达到临床完全缓解,随访超过10年。

主要发现

  • 15年膀胱癌死亡风险为11%(95% CI: 5.8%, 18%)。
  • 15年其他原因死亡竞争风险为44%(95% CI: 33%, 54%)。
  • 15年膀胱切除风险为11%(95% CI: 5.9%, 18%)。
  • 保留膀胱结局近似40:40:10:10分布,分别对应其他原因死亡、带膀胱存活、膀胱切除和膀胱癌死亡。
  • 41例带膀胱存活患者中位随访14年(IQR 11, 20),三分之一出现局部复发,且10年后仍有复发概率。

临床怎么用

  • 临床决策时应向符合理想标准的患者说明长期保留膀胱的概率与超额死亡风险。
  • 保留膀胱后需终身监测局部复发,因复发可发生于10年后。

局限性

  • 研究为单机构回顾性设计,结果可能不适用于其他场景或不符合理想标准的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Bladder preservation is a desired goal for most patients with muscle-invasive bladder cancer, although select few are ideal candidates based on established criteria. Heterogenous cohorts with short follow-up hinder assessment of true risks/benefits for ideal candidates. We describe long-term outcomes in patients with muscle-invasive bladder cancer, meeting established ideal criteria for bladder preservation, treated initially with systemic therapy and transurethral resection (TUR). MATERIALS AND METHODS: We conducted an institutional retrospective review of 101 prospectively monitored patients meeting "ideal" criteria for bladder preservation achieving a clinical complete response to cisplatin-based chemotherapy and TUR from 1994 to 2015, with > 10 years of follow-up. Primary end points were bladder-intact survival, local recurrence-free survival, and cancer-specific survival. RESULTS: Fifteen-year risk of death from bladder cancer was 11% (95% CI: 5.8%, 18%), with the competing risk of death from other causes 44% (95% CI: 33%, 54%) and cystectomy risk of 11% (95% CI: 5.9%, 18%). Bladder preservation outcomes were near 40:40:10:10 for death from another cause, alive with an intact bladder, cystectomy, and death from bladder cancer. Of 41 patients alive with their bladder intact, median (IQR) follow-up time was 14 (11, 20) years. One-third relapsed locally, with the probability persisting beyond 10 years, necessitating lifetime surveillance. Our findings may not be generalizable to other settings or to patients not meeting "ideal" criteria. CONCLUSIONS: Bladder preservation with neoadjuvant chemotherapy with TUR is a viable option for select patients meeting established selection criteria. Patients and physicians must consider the probabilities of long-term bladder preservation vs excess mortality when electing bladder-sparing.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Donat SM, Tin AL, Vickers AJ, et al. Neoadjuvant Chemotherapy With Transurethral Resection for Bladder Preservation: 15-Year Follow-Up of the Retained Bladder. J Urol. 2025. PMID: 40768675. doi:10.1097/JU.0000000000004704

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。